Gino Santini - Horizon Pharma Independent Director
| HZNPDelisted Stock | USD 116.30 0.00 0.00% |
Director
Mr. Gino Santini is Independent Director of the Company. Mr. Santini currently serves as the chairman of the board of directors of AMAG Pharmaceuticals, Inc., a public biopharmaceutical company, and serves on the board of directors of Intercept Pharmaceuticals, Inc., Collegium Pharmaceutical, Inc. and Allena Pharmaceuticals, Inc., all of which are public biopharmaceutical companies. Mr. Santini also serves on the board of directors of Artax Biopharma Inc. and Intarcia Therapeutics, Inc., each a private biopharmaceutical company, and is retired from a distinguished career with Eli Lilly and Company, a public pharmaceutical company. Mr. Santini previously served on the board of directors of Sorin SpA, a public medical products group, from 2012 to 2015, when it was acquired by LivaNova PLC and Vitae Pharmaceuticals, Inc., a public biotechnology company, from 2014 to 2016, when it was acquired by Allergan plc. During his tenure at Eli Lilly and Company from June 1983 to December 2010, Mr. Santini held various leadership positions since 2012.
| Age | 61 |
| Tenure | 12 years |
| Phone | 353 1 772 2100 |
| Web | https://www.horizontherapeutics.com |
Horizon Pharma Management Efficiency
The company has return on total asset (ROA) of 0.0444 % which means that it generated a profit of $0.0444 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0854 %, meaning that it created $0.0854 on every $100 dollars invested by stockholders. Horizon Pharma's management efficiency ratios could be used to measure how well Horizon Pharma manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 2.56 B in liabilities with Debt to Equity (D/E) ratio of 0.53, which is about average as compared to similar companies. Horizon Pharma PLC has a current ratio of 3.88, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Horizon Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Horizon Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Horizon Pharma PLC sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Horizon to invest in growth at high rates of return. When we think about Horizon Pharma's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Paul Bulcke | Roche Holding Ltd | 64 | |
| Ann Fudge | Novartis AG ADR | 70 | |
| Gabrielle Sulzberger | Eli Lilly and | 60 | |
| Robert Castaigne | Sanofi ADR | 70 | |
| Mark McClellan | Johnson Johnson | 57 | |
| Julia Haller | Bristol Myers Squibb | 66 | |
| Christine Seidman | Merck Company | 68 | |
| Fabienne Lecorvaisier | Sanofi ADR | 55 | |
| Simon Moroney | Novartis AG ADR | 62 | |
| William Kaelin | Eli Lilly and | 63 | |
| Bonnie Bassler | Sanofi ADR | N/A | |
| William Perez | Johnson Johnson | 71 | |
| Peter Voser | Roche Holding Ltd | 59 | |
| Frans Houten | Novartis AG ADR | 61 | |
| Marschall Runge | Eli Lilly and | 66 | |
| Jose Baselga | Bristol Myers Squibb | 57 | |
| Judith Pelham | Amgen Inc | 69 | |
| Ian Davis | Johnson Johnson | 70 | |
| Roxanne Austin | AbbVie Inc | 60 | |
| Leslie Brun | Merck Company | 68 | |
| Bruce Burlington | AstraZeneca PLC ADR | 67 | |
Management Performance
| Return On Equity | 0.0854 | |||
| Return On Asset | 0.0444 |
Horizon Pharma PLC Leadership Team
Elected by the shareholders, the Horizon Pharma's board of directors comprises two types of representatives: Horizon Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Horizon. The board's role is to monitor Horizon Pharma's management team and ensure that shareholders' interests are well served. Horizon Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Horizon Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ronald Pauli, Independent Director | ||
| Pascale Witz, Director | ||
| Thomas Watkins, Independent Director | ||
| Jeffrey Himawan, Independent Director | ||
| William Daniel, Independent Director | ||
| Michael DesJardin, Executive Vice President - Technical Operations | ||
| Sean JD, Exec Counsel | ||
| Robert Carey, Chief Bus. Officer and Executive VP | ||
| Vikram Karnani, Senior Vice President - Rheumatology Business Unit | ||
| Jeffrey Sherman, Chief Medical Officer, Executive Vice President - Development, Regulatory Affairs and Manufacturing | ||
| Barry Moze, COO and Executive VP | ||
| Patrick McIlvenny, VP Officer | ||
| Virinder Nohria, Director | ||
| Aaron Cox, Exec CFO | ||
| Geoffrey Curtis, Senior Vice President - Corporate Communications | ||
| Timothy Ackerman, Senior Vice President - Commercial Operations | ||
| David Happel, Executive Vice President - Orphan Business Unit | ||
| ShaoLee Lin, Executive Vice President Head of Research and Development, Chief Scientific Officer | ||
| Eric Mosbrooker, Senior Vice President Orphan Business Unit | ||
| David Kelly, Executive Vice President Company Secretary and Managing Director, Ireland | ||
| Brian Beeler, Executive Vice President General Counsel | ||
| Paul Hoelscher, CFO and Executive VP of Fin. | ||
| FACP FACP, Ex Officer | ||
| Irina Konstantinovsky, Chief Human Resource Officer, Executive Vice President | ||
| Jane Gonnerman, Office Staff | ||
| Gino Santini, Independent Director | ||
| Timothy Walbert, Chairman, CEO and Pres | ||
| George Hampton, Executive Vice President - Orphan and Primary Care Business Units and International Operations | ||
| John Thomas, Executive Vice President Strategy and Investor Relations | ||
| Tina Ventura, Senior Vice President Investor Relations | ||
| James Shannon, Director | ||
| Andy Pasternak, Ex Officer | ||
| Michael Grey, Lead Independent Director |
Horizon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Horizon Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0854 | |||
| Return On Asset | 0.0444 | |||
| Profit Margin | 0.12 % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 26.87 B | |||
| Shares Outstanding | 229 M | |||
| Shares Owned By Insiders | 1.18 % | |||
| Shares Owned By Institutions | 98.82 % | |||
| Number Of Shares Shorted | 7.1 M | |||
| Price To Earning | 32.55 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in Horizon Stock
If you are still planning to invest in Horizon Pharma PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Horizon Pharma's history and understand the potential risks before investing.
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |